tyrosine has been researched along with Coronary Artery Disease in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.67) | 18.2507 |
| 2000's | 36 (60.00) | 29.6817 |
| 2010's | 20 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dager, WE; Walker, EA | 1 |
| Afshinnia, F; Byun, J; Gadegbeku, CA; Kretzler, M; Magnone, MC; Pennathur, S; Valastro, B; Whatling, C; Zeng, L | 1 |
| Clofent-Sanchez, G; Dieryck, W; Hemadou, A; Jacobin-Valat, MJ; Jayaprakash, NS; Joucla, G; Lokeshwaran, K; Prasanna, RR; Santarelli, X; Venkataraman, K; Vijayalakshmi, MA | 1 |
| Cai, GJ; He, GP; Huang, ZY; Qi, CP | 1 |
| Haselden, V; Koeth, RA; Tang, WH | 1 |
| Ding, FH; Du, R; Hu, J; Liao, ML; Shen, WF; Wang, XL; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
| Bencsik, P; Csont, T; Ferdinandy, P; Kiss, K; Kolossváry, M; Kupai, K; Maurovich-Horvat, P; Merkely, B; Sasi, V; Ungi, I | 1 |
| Carvalho, AL; Favarato, D; Garcia, RM; Hueb, W; Kalil Filho, R; Maranhão, RC; Ramires, JA; Rezende, PC; Roggério, A; Segre, CA; Sprandel, Mda C; Strunz, CM | 1 |
| Ceron, CS; Luizon, MR | 1 |
| Bencsik, P; Ferdinandy, P; Görbe, A; Kiss, K | 1 |
| Chen, X; Hill, MA; Park, Y; Zhang, C; Zhang, H | 1 |
| Akao, H; Aoki, H; Fujibayashi, K; Kajinami, K; Kawai, Y; Kitayama, M; Motoyama, A; Nakanishi, H; Saito, K; Saito, R; Takeuchi, M; Tsuchiya, T; Wakasa, M; Watanabe, M | 1 |
| Juergens, CP; Winter, JP | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S | 1 |
| Zijlstra, F | 1 |
| Andreotti, F; Brancati, M; Burzotta, F; Crea, F; De Vita, M; Giammarinaro, M; Leone, AM; Mazzari, MA; Niccoli, G; Porto, I; Schiavoni, G; Talarico, GP; Todaro, D; Trani, C | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| Agewall, S; Kublickiene, K; Paier, A | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Furukawa, S; Kimura, H; Kon, N; Matsumoto, K; Mukaida, M; Murakami-Murofushi, K; Sone, H; Yamakura, F | 1 |
| Bongo, AS; Cavallino, C; Lazzero, M; Lupi, A; Rognoni, A; Sansa, M; Secco, GG | 1 |
| Cheng, KH; Chu, CS; Kuo, HF; Lai, WT; Lee, KT; Lee, MY; Lin, TH; Sheu, SH; Su, HM; Voon, WC | 1 |
| Steinhubl, SR | 1 |
| Berger, A; Freeman, A | 1 |
| Daiber, A; Münzel, T | 1 |
| Doulias, PT; Greco, TM; Hazen, SL; Ischiropoulos, H; Lightfoot, R; Martinez, M; Parastatidis, I; Tang, WH; Tenopoulou, M; Thomson, L; Tsika, E; Wu, Y | 1 |
| Rai, S; Zulli, A | 1 |
| Jacobs, C; Kelm, M; Meila, D; Scharf, RE; Schrör, K; Strauer, BE; Weber, AA; Weber, S; Zotz, RB | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Brunet, S; Levy, E; Mitchell, G; Rivard, GE; Suc, I | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Amikam, S; Gruberg, L | 1 |
| Casserly, IP; Chew, DP; Cohen, DJ; DiBattiste, PM; Hamm, C; Jia, G; Lakkis, N; Lange, RA; Meier, B; Moliterno, DJ; Stone, GW; Topol, EJ | 1 |
| Heitzer, T; Köke, K; Meinertz, T; Munzel, T; Ollmann, I | 1 |
| Gil, RJ; Rzezak, J | 1 |
| Aquilina, M; Branzi, A; Gaiba, W; Marrozzini, C; Marzocchi, A; Neri, S; Ortolani, P; Palmerini, T | 1 |
| Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC | 1 |
| Bergt, C; Brunzell, J; Byun, J; Chait, A; Geary, RL; Green, PS; Heinecke, JW; Kassim, SY; McDonald, TO; O'brien, K; Oram, JF; Pennathur, S; Shao, B; Singh, P | 1 |
| Goldmann, BU; Heitzer, T; Munzel, T; Nowak, G; Ostad, MA; Warnholtz, A | 1 |
| Azar, RR; Badaoui, G; Germanos, M; Kassab, R; Klaymé, S; Naman, R; Salamé, E; Sarkis, A | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Deeb, RS; Gamss, C; Gavrilova, T; Gross, SS; Hajjar, DP; Hao, G; Kraemer, R; Lainé, M; Maeda, N; Shen, H; Summers, BD; Upmacis, RK | 1 |
| Akgul, O; Cam, N; Erdem, I; Kasikcioglu, H; Okmen, E; Samur, H; Simsek, D; Tartan, Z; Unal Dayi, S; Uyarel, H; Uzunlar, B | 1 |
| Dorsch, MP; Montague, D; Patterson, C; Rodgers, JE | 1 |
| Hashimoto, S; Hikichi, Y; Hirase, T; Imoto, Y; Inoue, T; Kato, T; Morooka, T; Node, K; Sendo, F; Takeda, Y | 1 |
| Cree, AJ; Goverdhan, SV; Lotery, AJ; Ye, S | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Anderson, JL; Bair, TL; Burke, JL; Casterella, PJ; Horne, B; May, HT; Muhlestein, JB; Pearson, RR; Revenaugh, JR | 1 |
| Accavitti, MA; Anderson, PG; Beckmann, JS; Chen, J; Tarpey, MM; White, CR; Ye, YZ | 1 |
| Albala, A; Barbone, A; Cannon, PJ; Michler, RE; Ming, M; Ravalli, S; Szabolcs, M | 1 |
| Depre, C; Havaux, X; Renkin, J; Vanoverschelde, JL; Wijns, W | 1 |
| Sax, FL; Snapinn, SM; Théroux, P; Zhao, XQ | 1 |
| Moliterno, DJ | 1 |
| Asai, Y; Esaki, T; Hayashi, T; Iguchi, A; Kano, H; Kumar, TN; Muto, E; Sumi, D | 1 |
| Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Bertrand, M; Cohen, DJ; Cohen, EA; Cohen, M; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Moses, JW; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ; Wolski, K | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Snapinn, SM; Theroux, P | 1 |
2 review(s) available for tyrosine and Coronary Artery Disease
| Article | Year |
|---|---|
The role of tirofiban in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Cost-Benefit Analysis; Drug Design; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2008 |
Update on glycoprotein IIb/IIIa: role in primary coronary intervention.
Topics: Abciximab; Angioplasty; Animals; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2011 |
16 trial(s) available for tyrosine and Coronary Artery Disease
| Article | Year |
|---|---|
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Creatine Kinase, MB Form; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Prosthesis Design; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Up-Regulation | 2015 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardium; Necrosis; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
Topics: Acute Disease; Aged; Angina Pectoris; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Fees, Pharmaceutical; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Smoking; Statistics as Topic; Stroke Volume; Survival Analysis; Syndrome; Tirofiban; Tyrosine | 2002 |
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Coagulation; Blood Coagulation Tests; Clinical Trials as Topic; Coronary Artery Disease; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Time Factors; Tirofiban; Tyrosine | 2003 |
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Topics: Acetylcholine; Biological Availability; Blood Flow Velocity; Blood Platelets; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Eptifibatide; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Donors; omega-N-Methylarginine; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Plethysmography; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents; Vasomotor System | 2003 |
Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Topics: Angioplasty, Balloon, Coronary; Arkansas; Coronary Artery Disease; Eptifibatide; Female; Humans; Infusions, Intravenous; Male; Mississippi; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tennessee; Tirofiban; Tyrosine; United States | 2004 |
Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
Topics: Aged; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; CD40 Ligand; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening.
Topics: Amidohydrolases; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Female; GPI-Linked Proteins; Humans; Hydrolases; Inflammation; Male; Neutrophil Activation; Neutrophils; Regression Analysis; Respiratory Burst; Stents; Time Factors; Tunica Intima; Tyrosine | 2006 |
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome managemen
Topics: Aged; Angina, Unstable; Anticoagulants; Arteriosclerosis; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Thrombosis; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee.
Topics: Acetates; Adult; Aged; Cohort Studies; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Tyrosine | 2000 |
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Severity of Illness Index; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS
Topics: Acute Disease; Aged; Coronary Artery Disease; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Assessment; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
42 other study(ies) available for tyrosine and Coronary Artery Disease
| Article | Year |
|---|---|
Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Intraoperative Care; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Renal Dialysis; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Oxidative Stress; Peroxidase; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index; Tyrosine; Young Adult | 2017 |
Development of anti-chloro
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Apolipoprotein A-I; Atherosclerosis; Biomarkers; Coronary Artery Disease; Disease Models, Animal; Halogenation; Humans; Immunologic Tests; Lipoproteins, HDL; Mice, Knockout, ApoE; Oxidation-Reduction; Plaque, Atherosclerotic; Predictive Value of Tests; Reproducibility of Results; Tyrosine | 2019 |
Lack of association between a common polymorphism of the endothelial lipase gene and early-onset coronary artery disease in a Chinese Han population.
Topics: Asian People; Case-Control Studies; Coronary Artery Disease; Cytosine; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Lipase; Male; Middle Aged; Polymorphism, Single Nucleotide; Tyrosine | 2014 |
Myeloperoxidase in cardiovascular disease.
Topics: Biomarkers; Case-Control Studies; Coronary Artery Disease; Free Radicals; Gene Expression; Heart Failure; Humans; Immunity, Innate; Peroxidase; Plaque, Atherosclerotic; Prognosis; Reactive Nitrogen Species; Reactive Oxygen Species; Survival Analysis; Tyrosine | 2013 |
Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients.
Topics: Aged; Biomarkers; Coronary Artery Disease; Female; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Nitrogen; Pilot Projects; Tyrosine; Urea | 2015 |
Troponin in diabetic patients with and without chronic coronary artery disease.
Topics: Aged; Biomarkers; Case-Control Studies; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oxidation-Reduction; Peroxidase; Risk Factors; Troponin C; Tyrosine | 2015 |
Plasma matrix metalloproteinases in coronary artery disease patients.
Topics: Coronary Artery Disease; Female; Heart; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Tyrosine | 2016 |
Response to letter entitled Plasma MMPs in CAD patients by Ceron CS et al.
Topics: Coronary Artery Disease; Female; Heart; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Tyrosine | 2016 |
Regulation of Coronary Endothelial Function by Interactions between TNF-α, LOX-1 and Adiponectin in Apolipoprotein E Knockout Mice.
Topics: Adiponectin; Animals; Antibodies, Neutralizing; Apolipoproteins E; Arterioles; Coronary Artery Disease; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidase 4; NADPH Oxidases; NF-kappa B; Phenotype; Scavenger Receptors, Class E; Signal Transduction; Tumor Necrosis Factor-alpha; Tyrosine; Vasodilation; Vasodilator Agents | 2015 |
Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products.
Topics: Aged; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Glycation End Products, Advanced; Humans; Male; Middle Aged; Prediabetic State; Severity of Illness Index; Tyrosine | 2017 |
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Expression of heat shock proteins and nitrotyrosine in small arteries from patients with coronary heart disease.
Topics: Adult; Aged; Arteries; Case-Control Studies; Chaperonin 60; Coronary Artery Disease; Female; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Male; Middle Aged; Molecular Chaperones; Oxidative Stress; Subcutaneous Fat; Tyrosine | 2009 |
Effect of endurance exercise training on oxidative stress in spontaneously hypertensive rats (SHR) after emergence of hypertension.
Topics: Age Factors; Aldehydes; Animals; Aorta; Blood Pressure; Coronary Artery Disease; Fluoroimmunoassay; Hypertension; Motor Activity; Nitric Oxide; Oxidative Stress; Physical Conditioning, Animal; Physical Endurance; Rats; Rats, Inbred SHR; Superoxide Dismutase; Superoxides; Tyrosine | 2010 |
Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes.
Topics: Aged; Biomarkers; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Inflammation Mediators; Interleukin-6; Logistic Models; Male; Middle Aged; Odds Ratio; Prediabetic State; Risk Assessment; Risk Factors; Taiwan; Time Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2012 |
The illusion of "optimal" platelet inhibition.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Blood Platelets; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Tirofiban; Tyrosine | 2012 |
Imaging of left main coronary artery thrombus with CT coronary angiography.
Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Echocardiography; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2012 |
Increased circulating levels of 3-nitrotyrosine autoantibodies: marker for or maker of cardiovascular disease?
Topics: Coronary Artery Disease; Epitopes; Female; Humans; Immunoglobulins; Male; Tyrosine | 2012 |
Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease.
Topics: Aged; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Epitopes; Female; Humans; Immune System; Immunoglobulins; Male; Middle Aged; Tyrosine | 2012 |
Lack of cell stress markers in fibrous cap cells in the left main coronary artery.
Topics: Animals; Biomarkers; Coronary Artery Disease; Coronary Vessels; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endothelial Cells; Fibrosis; Heat-Shock Proteins; Heme Oxygenase-1; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type II; Plaque, Atherosclerotic; Rabbits; Stress, Physiological; Transcription Factor CHOP; Tyrosine | 2013 |
Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Antigens, Human Platelet; Case-Control Studies; Coronary Artery Disease; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Incidence; Integrin beta3; Male; Middle Aged; P-Selectin; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Tirofiban; Tyrosine | 2002 |
Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B.
Topics: Animals; Antibodies; Apolipoproteins; Binding Sites; CD36 Antigens; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Endocytosis; Lipoproteins, HDL; Macrophages; Membrane Proteins; Mice; Oxidative Stress; Poly I; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Scavenger; Scavenger Receptors, Class A; Scavenger Receptors, Class B; Sterol Esterase; Tyrosine | 2003 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft.
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Radiography; Saphenous Vein; Thromboembolism; Tirofiban; Tyrosine | 2003 |
[Angiogram of the month].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Fibrinolytic Agents; Humans; Male; Middle Aged; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Phosphorus Radioisotopes; Reoperation; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species.
Topics: Arteries; Arteriosclerosis; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Epitopes; Gas Chromatography-Mass Spectrometry; Humans; Immunohistochemistry; Inflammation; Lipid Peroxides; Lipoproteins, HDL; Mass Spectrometry; Nitric Oxide; Nitrogen; Oxygen; Peroxidase; Peroxynitrous Acid; Reactive Nitrogen Species; Taurine; Time Factors; Tunica Intima; Tyrosine | 2004 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production.
Topics: Animals; Aorta; Apolipoproteins E; Blotting, Northern; Blotting, Western; Cells, Cultured; Coronary Artery Disease; Eicosanoids; Female; Fluorescent Antibody Technique; Immunohistochemistry; Male; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Tyrosine | 2006 |
Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
Topics: Adult; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocardiography; Female; Fibrinolytic Agents; Heart Conduction System; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Reproducibility of Results; Research Design; Retrospective Studies; Stents; Stroke Volume; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis.
Topics: Aged; Atherosclerosis; Cholesterol; Complement Factor H; Coronary Artery Disease; Female; Histidine; Humans; Male; Middle Aged; Polymorphism, Genetic; Triglycerides; Tyrosine | 2006 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2008 |
Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry.
Topics: Cell Nucleus; Coronary Artery Disease; Coronary Vessels; Humans; Immunoenzyme Techniques; Macrophages; Middle Aged; Nitric Oxide; Oxidation-Reduction; Tyrosine | 1994 |
Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease.
Topics: Adult; Child; Child, Preschool; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Endothelium, Vascular; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Heart Transplantation; Humans; In Situ Hybridization; Macrophages; Male; Middle Aged; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; RNA, Messenger; Tyrosine | 1998 |
Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque.
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Coronary Artery Disease; Coronary Vessels; Female; Humans; Immunohistochemistry; Macrophages; Male; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Tumor Necrosis Factor-alpha; Tyrosine | 1999 |
Expression of inducible nitric oxide synthase and Fas/Fas ligand correlates with the incidence of apoptotic cell death in atheromatous plaques of human coronary arteries.
Topics: Aged; Aged, 80 and over; Apoptosis; Coronary Artery Disease; Coronary Vessels; Fas Ligand Protein; fas Receptor; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Membrane Glycoproteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Tyrosine | 2000 |
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
Topics: Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Europe; Fibrinolytic Agents; Health Care Costs; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |